ReviewMalaria journal2009
A retrospective analysis of the change in anti-malarial treatment policy: Peru.
Review in Malaria journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- How contexts and issues influence the use of policy-relevant research syntheses: a critical interpretive synthesis.The Milbank quarterly · 2013Pooled it
- Efficacy and effectiveness of mefloquine and artesunate combination therapy for uncomplicated Plasmodium falciparum malaria in the Peruvian Amazon.The American journal of tropical medicine and hygiene · 2011Trial
- Molecular characterization of the Plasmodium falciparum k13 gene helix domain in samples from native communities of Condorcanqui, Amazonas, PerúBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Replacement ofFrontiers in cellular and infection microbiology · 2022Article
- Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria in seven countries.Malaria journal · 2021Article
- Population genomics and evidence of clonal replacement of Plasmodium falciparum in the Peruvian Amazon.Scientific reports · 2021Article
- Simultaneous detection of Plasmodium vivax dhfr, dhps, mdr1 and crt-o resistance-associated mutations in the Colombian Amazonian region.Malaria journal · 2018Article
- Micro-heterogeneity of malaria transmission in the Peruvian Amazon: a baseline assessment underlying a population-based cohort study.Malaria journal · 2017Article
- Changing the policy for intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy in Malawi.Malaria journal · 2017Review
- Spatio-temporal analysis of malaria incidence in the Peruvian Amazon Region between 2002 and 2013.Scientific reports · 2017Article
- Epidemiology of Plasmodium vivax Malaria in Peru.The American journal of tropical medicine and hygiene · 2016Article
- Accelerating to Zero: Strategies to Eliminate Malaria in the Peruvian Amazon.The American journal of tropical medicine and hygiene · 2016Article
- Assessing malaria transmission in a low endemicity area of north-western Peru.Malaria journal · 2013Article
- The history of 20th century malaria control in Peru.Malaria journal · 2013Review
- Embedding health policy and systems research into decision-making processes in low- and middle-income countries.Health research policy and systems · 2013Review
- The spatial and temporal patterns of falciparum and vivax malaria in Perú: 1994-2006.Malaria journal · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNational malaria control programmes must deal with the complex process of changing national malaria treatment guidelines, often without guidance on the process of change. Selecting a replacement drug is only one issue in this process. There is a paucity of literature describing successful malaria treatment policy changes to help guide control programs through this process.
objectivesTo understand the wider context in which national malaria treatment guidelines were formulated in a specific country (Peru).
methodsUsing qualitative methods (individual and focus group interviews, stakeholder analysis and a review of documents), a retrospective analysis of the process of change in Peru's anti-malarial treatment policy from the early 1990's to 2003 was completed.
resultsThe decision to change Peru's policies resulted from increasing levels of anti-malarial drug resistance, as well as complaints from providers that the drugs were no longer working. The context of the change occurred in a time in which Peru was changing national governments, which created extreme challenges in moving the change process forward. Peru utilized a number of key strategies successfully to ensure that policy change would occur. This included a) having the process directed by a group who shared a common interest in malaria and who had long-established social and professional networks among themselves, b) engaging in collaborative teamwork among nationals and between nationals and international collaborators, c) respect for and inclusion of district-level staff in all phases of the process, d) reliance on high levels of technical and scientific knowledge, e) use of standardized protocols to collect data, and f) transparency.
conclusionAlthough not perfectly or fully implemented by 2003, the change in malaria treatment policy in Peru occurred very quickly, as compared to other countries. They identified a problem, collected the data necessary to justify the change, utilized political will to their favor, approved the policy, and moved to improve malaria control in their country. As such, they offer an excellent example for other countries as they contemplate or embark on policy changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.